Inspections and Regulatory Harmonization
Alternative Tools

Workshop Session 2 – 26th January 2022
Inspections and Regulatory Harmonization

Alternative Tools
from a regulatory perspective

Susan Turcovski
Deputy Director
Office of Biological Products Operations
Office of Medical Products and Tobacco Operations
Office of Regulatory Affairs

Madu Dharmassena, Ph.D.
Senior Pharmaceutical Quality Assessor
Division of Biotechnology Manufacturing, Branch 2
Office of Pharmaceutical Manufacturing Assessment (OPMA)
Office of Pharmaceutical Quality (OPQ)
Center for Drug Evaluation and Research (CDER)
Regulations for inspections

• 601.20(a): A biologics license application shall be approved only upon examination of the product and upon a determination that the product complies with the standards established in the biologics license application and the requirements prescribed in the regulations in this chapter

• 601.20(b)(2)(c): No product shall be licensed if any part of the process would impair the assurances of continued safety, purity, and potency

• 600.20: Inspections shall be made by an officer of the Food and Drug Administration having special knowledge of the methods used in the manufacture and control of products
Alternative tools

- Alternative tools include
  - Assessment of records and other information requested under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act
  - Voluntary Remote Interactive Evaluation (RIE)
  - Review of inspection reports by inspectorates under a Mutual Recognition Agreement (MRA) and confidentiality agreements

- These alternative tools are **not** considered inspections

- 483 under Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) is not issued
Remote Interactive Evaluations (RIE)

A new tool?

Video conferences

Screen sharing records

• “Guidance on Remote Interactive Evaluations of Drug and Bioresearch Monitoring Facilities” – Published April 2021
  • Voluntary assessment of a facility where drugs are manufactured, processed, packed or held that uses remote interactive tools such as live stream or prerecorded videos
  • An RIE will not constitute an inspection
• FDA is assessing challenges with IT, infrastructure and equipment; regulatory strategies and limitations; establishment capabilities

www.fda.gov
Pros and Cons of Alternative tools

• Pros
  • Evaluation of a facility when travel is not feasible
  • Prioritize which establishments to perform on-site inspections

• Cons
  • The firm controls the camera and thus, regulators see what the firm wants to the regulators to see
  • Regulators can not use all their senses
  • Time difference
Inspections and Regulatory Harmonization: Alternative Tools

26 January 2022
WCBP Workshop

Søren Thuesen Pedersen
Novo Nordisk A/S
Quality Intelligence and Inspections

The Novo Nordisk Quality Mission:
Inspections and Regulatory Harmonization: Alternative Tools: As seen from a European pharmaceutical company
The burning platform after 11th March 2020

We need a ‘standardized’ way through this!
We needed to engage with peers and regulators

Activities started (almost immediately) in:

- **BioPhorum (BPOG)** Working Group on Remote Inspections (Guidance is in the link)
- **IFPMA** Task Force on Remote Inspection (PtC is in the link)
- **BIO** Inspection TF focus on remote inspections (USA)
- **EFPIA** Manufacturing Quality Expert Group, MQEG (Inspection survey is in the link)

• First question: Can we engage regulators to use each others work where applicable (Reliance) ?
Podcast

• BioPhorum Webinars – BioPhorum

BioPhorum introduces – developing good practices for remote inspections in the Covid era

📅 09th June, 2021

In normal conditions, regulatory inspections and audits are conducted on-site, however, travel and social restrictions due to the Covid-19 pandemic have forced regulatory inspections and audits of affiliates to be conducted remotely.

This is a very different way of working and a multi-company collaboration, comprising subject matter experts from 29 BioPhorum members, has shared case studies and discussed the practical factors that make remote inspections and audits effective. Learning from post-inspection feedback from inspectors has also been shared. This experience has been captured in Peer to peer practical guidance on remote inspections and audits.

In this podcast, a member of the collaboration, Søren Thuesen Pedersen, Senior Director of Quality Intelligence and External Affairs at Novo Nordisk, talks to Dawood Dassu, BioPhorum Fill Finish Lead.
Remote Inspections in Novo Nordisk 2020-2022:

- Russia
- Denmark
- Notified Body
- Korea
Lessons learned in Novo Nordisk

• Very, very resource intensive:
• Number of documents requested prior, during and after to the inspection vs. reviewed
• Requires a lot of practical coordination and rehearsals (IT platform, WebEx)
• Mapping of Wi-Fi!

• Inventions: Use of phones vs. scanning equipment
• The very ‘fancy’ optical equipment can be a help but in many instances a smartphone will do
• Trade secrets!
• Use of Affiliate Offices. Good and bad aspects.
• Translation is critical.
• Pre-recorded videos are labor intensive (Expert needs to be present at inspection too) vs. real-time streaming
Worth noticing on remote assessments

1. **MHRA** Putting patients first: A new era for our agency Delivery Plan 2021-2023:

   “Pilot voluntary ‘pre-inspection’ checks to fast track new applications for manufacturing licences and piloting the use of consultants as ‘compliance monitors’ in remediation cases by Q3, 2021/22; roll out of automated inspection reports and identify new risk-proportionate approaches with our international partners by Q4, 2021/22; embed file-sharing platforms for remote inspections and visual technology capabilities as a standard part of inspections in 2022/23.”

2. **ICMRA**: **Summit Report 1.-2. December 2021**

   - **PQKMS**: Two pilots have been developed: one on collaborative assessment between regions for post-approval change management protocols striving to achieve common outcomes, and the other one on hybrid inspections, where one region is physically performing the inspection on site and one or more other participating remotely.

   - Digital transformation of GCP and GMP inspections and clinical trials
Novo Nordisk Sharepoint site

We gather all information about remote assessment in one site

This SharePoint site is dedicated to material that might be useful when working with remote assessment processes. This can be Remote Assessments/Virtual Inspections from authorities, Remote Internal Audits and finally Remote Customer Audits.

In here you can find position papers from various industry associations, course material from internal and external events as well as link to relevant regulations.

Since many of the processes are so similar we encourage you to explore the site and use it as you see fit in your particular situation.
Our new Podcast series in Novo Nordisk

Quality Talks

• Remember to ”Follow” (Like and subscribe)
Remote assessments

Isabelle Lequeux
Regulatory Lead, Regulatory and Partners
Background

28 companies and 30 senior subject matter experts came together to face the new 2021 requirement for biomanufacturers to face remote assessments for site certification or product licensing.

The team shared experience and know-how on how to best to facilitate remote assessments to avoid delays and inefficiencies.

A good practice paper was delivered, with useful practical advice to help which is in line with the individual guidance from Health Authorities.

In general, industry experience of remote assessments is positive, but securing confidentiality remains a challenge, and there is significant increase in documentation requests and translations, ‘out-of-office’ hours Q&A and time zone differences does put a burden on colleagues.

As the pandemic ebbs and flows there remains uncertainty as to what the Health Authority plans are for remote assessments.
Main elements of the BioPhorum consensus good practices

1. The more effective remote assessments involved a pre-work with the Inspector team

- **Clarify the purpose** and scope of the assessment
- **Set the appropriate timelines**, noting that additional preparation time is required for remote inspections, and more documents may be requested
- **Agree the stages** of the assessment (opening meeting, updates, meeting breaks, document review, Q&A, and closing meeting)
- **Align on how inspectors will provide periodic updates** (e.g. daily wrap-ups, daily check-out lists)
- **Confirm how data will be delivered** to the inspectors (which system(s) will be used)
- **Align on the format** - how documents will be provided and how the virtual (video) facility tour will be conducted (e.g. live or recorded). Decide balance between document review, presentations and simulation of an on-site experience
- **Align on the language** of the assessment and any translation needs. Note that ‘live’ translation can be difficult during a remote assessment
- **Agree on communication pathways** for any questions or clarifications on documents – Decide when it will be acceptable to provide an overview/response letter rather than submitting an entire document
Main elements of the BioPhorum consensus good practices

Some good practices during remote inspections

- Use and agreed plan for responsibilities covering decision making and information flow (a RACI model is a useful tool for this)

- Assign a moderator for the virtual conference inspection rooms. Control the number of internal observers on the call (place control on chat threads) just as you would with an on-site inspection

- Conduct daily wrap-up meetings with the inspectors and reconciliation meetings with the internal inspection team

- Have an IT technical expert on standby

- Have key documents translated in advance (simultaneous translations are difficult)

- Prepare storyboards to clarify or introduce topics; with diagrams and photographs ready to explain any technically complicated topics

- Expect inspectors to want to stop and zoom in on features to allow them to absorb what they see, as the field of view is narrower on video. They may also ask to move the video forward or backward – they are in control

- Directly check with inspectors to know if a question has been fully answered or a document review completed – prepare to be flexible

- Be mindful that it isn’t possible to talk the inspector through documents as happens during an on-site inspection
Main elements of the BioPhorum consensus good practices

Available IT has been used to date, and new VR tools are being tested

- **Meeting conferencing platforms** (e.g. MS Teams, Google Meet, Zoom, WebEx, etc.)
- **Document-sharing platforms** (e.g. OneDrive or EngageZone)
- **Document cameras** (e.g. ELMO) Video-enabled devices (e.g. smart glasses, cellphones, tablets)
- **Supporting equipment and applications** – Video-stabilizing equipment (e.g. gimbal, selfie stick) – Audio enhancers (e.g. microphones used to reduce noise in high-traffic areas) – Cameras suitable for solvent-rich API facilities
Questions to the Audience

• From your point of view, what are the key challenges of remote assessments (industry perspective and regulatory perspective)?

• How are our organizations responding to these challenges?

• Are remote assessments here to stay or will they disappear when site visits and the physical presence is back on a routine basis? Is there a place for remote assessments besides audits/inspections/evaluations?

• Are inspections needed as often as they take place? Could we rely more on the work carried out by other regulatory agencies? Can we utilize existing Mutual Reliance Agreements (MRA’s) in a better way? What are the main blockers to reliance on a GMP inspection by a Pharmaceutical Inspection Co-operation Scheme (PIC/S) member to be accepted by another PIC/S member?